Evidence map›Paper›PMID 36253511›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023

Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

Linda Söderberg, Malin Johannesson, Patrik Nygren, Hanna Laudon, Fredrik Eriksson, Gunilla Osswald, Christer Möller, Lars Lannfelt

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 9 pooled it
44.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 9 syntheses or guidelines pooled it, 398 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Linda SöderbergBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Malin JohannessonBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Patrik NygrenBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Hanna LaudonBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Fredrik ErikssonBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Gunilla OsswaldBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Christer MöllerBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden.
Lars LannfeltBioArctic AB, Warfvinges väg 35, 112 51, Stockholm, Sweden. Lars.Lannfelt@pubcare.uu.se.ORCID 0000-0001-9839-659X
BioArctic Neuroscience (Sweden) · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers, protofibrils, and insoluble fibrils in plaques. Oligomers and protofibrils have been shown to be toxic, and removal of these aggregates might represent an effective treatment for AD. We have characterized the binding properties of lecanemab, aducanumab, and gantenerumab to different Aβ species with inhibition ELISA, immunodepletion, and surface plasmon resonance. All three antibodies bound monomers with low affinity. However, lecanemab and aducanumab had very weak binding to monomers, and gantenerumab somewhat stronger binding. Lecanemab was distinctive as it had tenfold stronger binding to protofibrils compared to fibrils. Aducanumab and gantenerumab preferred binding to fibrils over protofibrils. Our results show different binding profiles of lecanemab, aducanumab, and gantenerumab that may explain clinical results observed for these antibodies regarding both efficacy and side effects.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedHumansaducanumabAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedgantenerumablecanemabAducanumabAmyloid-beta speciesGantenerumabLecanemabTherapeutic antibodies

Identifiers

PMID36253511
PMCPMC10119362
OpenAlexW4306644813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.